Welcome to LookChem.com Sign In|Join Free

CAS

  • or
2-(9-Bromononyl-1-oxy)tetrahydropyran is a synthetic intermediate with a unique chemical structure that features a tetrahydropyran ring and a bromononyl-1-oxy group. 2-(9-BROMONONYL-1-OXY)TETRAHYDROPYRAN plays a significant role in the synthesis of various pharmaceutically relevant molecules.

55695-90-4 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 55695-90-4 Structure
  • Basic information

    1. Product Name: 2-(9-BROMONONYL-1-OXY)TETRAHYDROPYRAN
    2. Synonyms: 2-(9-BROMONONYL-1-OXY)TETRAHYDROPYRAN;2-(9-Bromononyloxy)tetrahydropyran
    3. CAS NO:55695-90-4
    4. Molecular Formula: C14H27BrO2
    5. Molecular Weight: 307.27
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 55695-90-4.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 360.8°Cat760mmHg
    3. Flash Point: 136.4°C
    4. Appearance: /
    5. Density: 1.14g/cm3
    6. Vapor Pressure: 0mmHg at 25°C
    7. Refractive Index: 1.48
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. CAS DataBase Reference: 2-(9-BROMONONYL-1-OXY)TETRAHYDROPYRAN(CAS DataBase Reference)
    11. NIST Chemistry Reference: 2-(9-BROMONONYL-1-OXY)TETRAHYDROPYRAN(55695-90-4)
    12. EPA Substance Registry System: 2-(9-BROMONONYL-1-OXY)TETRAHYDROPYRAN(55695-90-4)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 55695-90-4(Hazardous Substances Data)

55695-90-4 Usage

Uses

Used in Pharmaceutical Industry:
2-(9-Bromononyl-1-oxy)tetrahydropyran is used as a synthetic intermediate for the preparation of estradiol-adenosine hybrid compounds. These hybrid compounds are designed to inhibit type 1 17β-hydroxysteroid dehydrogenase, an enzyme involved in the regulation of estrogen levels, and have potential applications in the treatment of hormone-dependent disorders and cancers.
Additionally, 2-(9-Bromononyl-1-oxy)tetrahydropyran is used as a synthetic intermediate for the preparation of biphenylsulfonates. These biphenylsulfonates act as S1P1 receptor antagonists, which have potential applications in the treatment of various immune-related disorders, such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease, by modulating the immune cell trafficking and function.

Check Digit Verification of cas no

The CAS Registry Mumber 55695-90-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,6,9 and 5 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 55695-90:
(7*5)+(6*5)+(5*6)+(4*9)+(3*5)+(2*9)+(1*0)=164
164 % 10 = 4
So 55695-90-4 is a valid CAS Registry Number.
InChI:InChI=1/C14H27BrO2/c15-11-7-4-2-1-3-5-8-12-16-14-10-6-9-13-17-14/h14H,1-13H2

55695-90-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(9-bromononoxy)oxane

1.2 Other means of identification

Product number -
Other names 9-Bromononanol tetrahydropyran-2-yl ether

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:55695-90-4 SDS

55695-90-4Relevant articles and documents

Preparation method of (E,E,Z)-10, 12, 14-hexadecatriene acetate, composition and attractant core

-

Paragraph 0025; 0049-0050; 0052; 0061; 0063, (2021/02/10)

The invention relates to a preparation method of (E,E,Z)-10,12,14-hexadecatriene acetate, a Diaphania pyloalis attractant composition and an attractant core, and compared with the prior art, the preparation method of (E,E,Z)-10,12,14-hexadecatriene acetate has the advantages of cheap and easily available raw materials, high reaction yield, simple post-treatment, high isomerization purity of the synthesized compound, clean and environment-friendly process flow, and high activity in field. The Diaphania pyloalis attractant composition based on the (E,E,Z)-10,12,14-hexadecatriene acetate and theattractant core of the Diaphania pyloalis attractant composition have a remarkable moth-luring synergistic effect and can be stably and efficiently used for population monitoring, prevention and control of mulberry borers.

METABOLICALLY STABLE PRODRUGS

-

Paragraph 0073, (2020/01/24)

Provided are prodrugs of various therapeutic agents that provide enhanced bioavilabilty of the therapeutic agent, and methods of treatment conditions in a subject by administration of the one or prodrugs. As provided herein a prodrug includes a therapeutic agent covalently attached to a cap, the cap having a structure according to formula (I) where: R1 is a branched or linear substituted or unsubstituted C2-C6 alkyl, alkenyl, or alkynl; X is -S(0)2-; R2 is a branched or linear substituted or unsubstituted C4-C20 alkyl, alkenyl, or alkynyl; and R3 is -H, C3-C5 cycloalkyl, C3-C5 cycloheteroalkyl, -C(CH3)3, -CF3, -C(CF3)3, or a substituted or unsubstituted phenyl.

Antibacterial Activity of Hexadecynoic Acid Isomers toward Clinical Isolates of Multidrug-Resistant Staphylococcus aureus

Carballeira, Néstor M.,Chorna, Nataliya,Díaz, Damarith,Medina, Solymar,Mooney, Joseph,Morales-Guzmán, Christian,Ocasio-Malavé, Carlimar,Pereles-De-León, Tomás,Rivera-Román, Ashley,Sanabria-Ríos, David J.

, (2020/02/04)

In the present study, the structural characteristics that impart antibacterial activity to C16 alkynoic fatty acids (aFA) were further investigated. The syntheses of hexadecynoic acids (HDA) containing triple bonds at C-3, C-6, C-8, C-9, C-10, and C-12 were carried out in four steps and with an overall yield of 34–78%. In addition, HDA analogs containing a sulfur atom at either C-4 or C-5 were also prepared in 69–77% overall yields, respectively. Results from this study revealed that the triple bond at C-2 is pivotal for the antibacterial activity displayed by 2-HDA, while the farther the position of the triple bond from the carbonyl group, the lower its bactericidal activity against gram-positive bacteria, including clinical isolates of methicillin-resistant Staphylococcus aureus (CIMRSA) strains. The potential of 2-HDA as an antibacterial agent was also assessed in five CIMRSA strains that were resistant to Ciprofloxacin (Cipro) demonstrating that 2-HDA was the most effective treatment in inhibiting their growth when compared with either Cipro alone or equimolar combinations of Cipro and 2-HDA. Moreover, it was proved that the inhibition of S. aureus DNA gyrase can be linked to the antibacterial activity displayed by 2-HDA. Finally, it was determined that the ability of HDA analogs to form micelles can be linked to their decreased activity against gram-positive bacteria, since critical micellar concentrations (CMC) between 50 and 300 μg/mL were obtained.

LIPID NANOPARTICLE FORMULATIONS

-

Page/Page column 147-148, (2018/05/24)

Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.

SYNTHESIS OF PHEROMONES AND RELATED MATERIALS VIA OLEFIN METATHESIS

-

Paragraph 0110; 0230, (2018/09/12)

Methods for preparation of olefins, including 8- and 11-unsaturated monoenes and polyenes, via transition metathesis-based synthetic routes are described. Metathesis reactions in the methods are catalyzed by transition metal catalysts including tungsten-, molybdenum-, and ruthenium-based catalysts. The olefins include insect pheromones useful in a number of agricultural applications.

LIPID DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE

-

Page/Page column 143, (2018/11/10)

A method of treating a disease mediated by protein expression in adipose tissue by intraperitoneally administering a composition comprising a lipid nanoparticle encapsulating or associated with a therapeutic agent (e.g., a nucleic acid), thereby delivering the therapeutic agent to adipose tissue of the subject and altering protein expression in the adipose tissue is provided herein. A method for delivering a therapeutic agent to adipose tissue of a subject in need thereof is also provided.

LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS

-

Page/Page column 66, (2017/07/14)

Compounds are provided having the following structure (I) or (II): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, L, X, L, G1, G2, Z, a1, a2 and n are independently as defined herein for each of structures (I) and (II). Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Synthesis of specific deuterated derivatives of the long chained stratum corneum lipids [EOS] and [EOP] and characterization using neutron scattering

Sonnenberger, Stefan,Eichner, Adina,Schmitt, Thomas,Hau?, Thomas,Lange, Stefan,Langner, Andreas,Neubert, Reinhard H.H.,Dobner, Bodo

, p. 316 - 330 (2017/06/08)

The synthesis of specific deuterated derivatives of the long chained ceramides [EOS] and [EOP] is described. The structural differences with respect to the natural compounds are founded in the substitution of the 2 double bonds containing linoleic acid by a palmitic acid branched with a methyl group in 10-position. The specific deuteration is introduced both in the branched and in the terminal methyl group, which was realized by common methods of successive deuteration of carboxylic groups in 3 steps. These modified fatty acids resp. the corresponding ceramides [EOS] and [EOP] were prepared for neutron scattering investigations. First results of these investigations were presented in this manuscript showing that the deuterated compounds could be detected in the stratum corneum lipid model membranes. The deuterated ceramides [EOS] and [EOP] are valuable tools to investigate the influence of these long chained ceramide species on the nanostructure of stratum corneum lipid model membranes.

Compositions and methods for binding lysophosphatidic acid

-

Page/Page column 61-62, (2015/11/10)

Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Identification and synthesis of the male produced volatiles of the carrion beetle, Oxelytrum erythrurum (Coleoptera: Silphidae)

Fockink, Douglas H.,Martins, Camila B.C.,Zarbin, Paulo H.G.

, p. 5353 - 5356 (2015/09/01)

Necrophagous beetles belonging to the family Silphidae are recognized as potentially useful in forensic investigations (to estimate post mortem interval). Gas chromatography analyses of extracts of aerations of adult Oxelytrum erythrurum revealed the presence of two male-specific compounds. These compounds were identified as (Z)-1,10-nonadecadiene (major) and 1-nonadecene (minor) using microderivatizations of the natural male extract, such as hydrogenation, partial reduction and methylthiolation, mass spectrum comparisons, and co-injections with authentic standards. Both compounds might be components of a pheromone responsible for sexual communication in this species.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 55695-90-4